CNMD Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

36.249

Open

35.710

VWAP

34.85

Vol

433.28K

Mkt Cap

1.03B

Low

34.050

Amount

15.10M

EV/EBITDA(TTM)

10.29

Total Shares

30.11M

1.88B

EV/OCF(TTM)

13.20

P/S(TTM)

0.79

CONMED Corporation is a medical technology company which provides devices and equipment for surgical procedures. Its products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Its product line consists of orthopedic surgery and general surgery. Orthopedic surgery consists of sports medicine instrumentation and lower extremities instrumentation and implants, small bone, large bone and specialty-powered surgical instruments as well as imaging systems for use in minimally invasive surgical procedures and service fees related to the promotion and marketing of sports medicine allograft tissue. General surgery consists of a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, smoke evacuation devices, a line of cardiac monitoring products as well as electrosurgical generators and related instruments.

Events Timeline

(ET)

2026-06-17

17:00:00

CONMED Appoints John E. Gallagher as CFO

2026-05-20 (ET)

2026-05-20

08:40:00

Conmed Appoints Celine Martin and Jeff Mirviss to Board of Directors

2026-04-29 (ET)

2026-04-29

16:40:00

CONMED Q1 Revenue of $317M Beats Expectations

2026-04-29

16:40:00

Company Narrows FY26 Revenue View to $1.35B-$1.375B

News

5.0

06-17seekingalpha

CONMED Appoints New CFO John Gallagher Effective July 2026

5.0

06-17Newsfilter

CONMED Appoints New Chief Financial Officer

9.5

04-30seekingalpha

CONMED Q1 2026 Earnings Call Insights

9.5

04-29NASDAQ.COM

CONMED Reports Doubling of Q1 Profit, Raises Growth Outlook

9.5

04-29seekingalpha

CONMED Q1 Earnings Beat Expectations, Full-Year Outlook Raised

2.0

04-06NASDAQ.COM

CONMED Shares Enter Oversold Territory

5 Analyst Rating

Wall Street analysts forecast CNMD stock price to rise

1 Buy

4 Hold

0 Sell

Hold

Current: 0.000

Low

41.00

Averages

50.00

High

55.00

Current: 0.000

Low

41.00

Averages

50.00

High

55.00

BofA

Travis Steed

Neutral -> Underperform

downgrade

$40

AI Analysis

2026-06-29

Reason

BofA

Travis Steed

Price Target

$40

AI Analysis

2026-06-29

downgrade

Neutral -> Underperform

Reason

BofA analyst Travis Steed downgraded Conmed to Underperform from Neutral with an unchanged price target of $40. When dollars come back into medtech, the firm thinks they will gravitate towards higher growth, quality, large caps that are trading a historically low valuations, so it thinks Conmed underperforms other medtech stocks in the firm's coverage over a one-year period, the analyst tells investors.

BofA

Neutral

downgrade

$52 -> $40

2026-05-18

Reason

BofA

Price Target

$52 -> $40

2026-05-18

downgrade

Neutral

Reason

BofA lowered the firm's price target on Conmed to $40 from $52 and keeps a Neutral rating on the shares. After having hosted 34 medtech companies last week in Las Vegas, the firm updated several price targets for "the new reality of medtech valuations" in a year of few product cycles, ACA and utilization worries, inflation kicking up post-war, and "data centers over healthcare," the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CNMD

Unlock Now

Valuation Metrics

The current forward P/E ratio for Conmed Corp (CNMD.N) is 27.17, compared to its 5-year average forward P/E of 25.15. For a more detailed relative valuation and DCF analysis to assess Conmed Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

25.15

Current PE

27.17

Overvalued PE

35.35

Undervalued PE

14.94

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

14.46

Current EV/EBITDA

8.87

Overvalued EV/EBITDA

19.03

Undervalued EV/EBITDA

9.88

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

2.13

Current PS

0.74

Overvalued PS

3.09

Undervalued PS

1.17

Financials

AI Analysis

Annual

Quarterly

Whales Holding CNMD

Invenomic Capital Management LP

Trading Trends

People Also Watch

Frequently Asked Questions

What is Conmed Corp (CNMD) stock price today?

The current price of CNMD is 34.24 USD — it has decreased -2.48

What is Conmed Corp (CNMD)'s business?

What is the price predicton of CNMD Stock?

Wall Street analysts forecast CNMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNMD is50.00 USD with a low forecast of 41.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.